

## Evaluation of Antioxidant Activity of Some Imines Containing 1H-Benzimidazoles

### 1H-Benzimidazoller İçeren Bazı İminlerin Antioksidan Aktivitesinin Değerlendirilmesi

Rahman Basaran<sup>1</sup>, Gülgün Kılıçgil<sup>2</sup>, Benay Eke<sup>3</sup>

<sup>1</sup>School of Chemistry, University of Leeds, LS2 9JT, Leeds, United Kingdom

<sup>2</sup>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, 06560, Turkey

<sup>3</sup>Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Ankara University, Ankara, 06560, Turkey

#### ÖZ

**GİRİŞ ve AMAÇ:** Bu çalışmada, bazı 2-(2-fenil)-1H-benzo[d]imidazol-1-il)-N'-(arilmetilen) asetohidrazit türevlerinin in vitro antioksidan özellikleri araştırılmıştır.

**YÖNTEM ve GEREÇLER:** 1-12 numaralı bileşiklerin in vitro antioksidan aktiviteleri, lipid peroksidasyon (LPO) seviyelerinde sıçan karaciğer mikrozomal NADPH-bağımlı inhibisyonunun ve mikrozomal etoksiresorufin O-deetilaz (EROD) aktivitesinin belirlenmesiyle incelenmiştir.

**BULGULAR:** Tiyofen halkası içeren bileşik 6 dışında, sentezlenen tüm bileşikler LPO inhibisyon aktivitesi (%15-57) göstermiştir. Hemen hemen tüm bileşikler az miktarda EROD inhibe edici aktivite (%2-20) sergilemiştir.

**TARTIŞMA ve SONUÇ:** Benzimidazol halkasının 2. konumunda p-bromo fenil süstitüenti taşıyan bileşik 3, LPO seviyesinde %57 inhibisyona neden olan en aktif bileşik iken, butillenmiş hidroksitoluen (BHT) %65 inhibisyon göstermiştir. Sentezlenen bileşiklerin hiçbir EROD aktivitesi üzerinde belirgin bir inhibisyon etkisine sahip değildir.

**Anahtar Kelimeler:** Antioksidan, benzimidazol, imin, lipid peroksidasyon

#### ABSTRACT

**INTRODUCTION:** In this study, the in vitro antioxidant properties of some 2-(2-phenyl)-1H-benzo[d]imidazol-1-yl)-N'-(arylmethylene) acetohydrazide derivatives (1-12) were investigated.

**METHODS:** The in vitro antioxidant activity of compounds 1-12 were explored by determination of rat liver microsomal NADPH-dependent inhibition on lipid peroxidation (LPO) levels and microsomal ethoxyresorufin O-deethylase (EROD) activity.

**RESULTS:** All synthesised compounds had LPO inhibitory activities (15-57%) except compound 6 which contains thiophene ring. Almost all the compounds displayed slightly inhibitory activities (2-20%) on EROD.

**DISCUSSION AND CONCLUSION:** The most active compound 3 bearing p-bromophenyl substituent at the 2nd position of benzimidazole ring led to 57% inhibition on LPO level while butylated hydroxytoluene (BHT) showed 65% inhibition. None of the synthesized compounds had a marked inhibitory effect on EROD activity.

**Keywords:** Antioxidant, benzimidazole, imine, lipid peroxidation

cmrb@leeds.ac.uk  
0000-0001-9640-2730  
00447902047533  
30.09.2019  
31.10.2019

## INTRODUCTION

Antioxidant-defence mechanisms are present in living cells to maintain cellular homeostasis and survival by preventing cellular damages caused by oxidative stress in various diseases.<sup>1-2</sup> Impairment of antioxidant mechanisms causes the balance between antioxidant defences and oxygen-derived free radicals to shift in favour of free radicals, resulting in oxidative stress. Therefore, the synthesis of novel drugs with antioxidants and free radical scavenging properties can help to treat and/or prevent the diseases induced by insufficient antioxidant capacity. It is well recognized that lipid peroxidation (LPO) is a free-radical-mediated chain process whereby results in oxidative damage to cell membranes and other lipid-containing structures.<sup>3</sup> It is an important tool to probe the antioxidant capacity of a novel compound. Almost all LPO products have been long reported to possess carcinogenic and/or mutagenic effects. Moreover, reactive oxygen species (ROS) are generated by a variety of cellular mechanisms including Cytochrome P450 (CYP450) enzymes which catalyse a wide range of endogenous and exogenous substances, particularly CYP1A1/2 have great importance in NADPH-dependent LPO. Probing the effects of synthesised compounds on LPO levels and CYP450 system is, therefore, crucial.<sup>4</sup>

Benzimidazoles have become an attractive pharmacophore in drug design and discovery and exhibit a wide range of biological activities e.g. antimicrobial,<sup>5,6,7</sup> antiparasitic,<sup>8</sup> antihistaminic,<sup>9</sup> anticancer,<sup>10-15</sup> antiallergic,<sup>16</sup> and antioxidant.<sup>17-26</sup> The synthesis, characterisation, and antioxidant capacities of some benzimidazole derivatives containing thiadiazole, triazole, oxadiazole and thiazolidinone rings at the 1<sup>st</sup> position have been reported in the previous studies,<sup>6,18-21,23-25</sup> and most of these compounds have been shown to possess substantial antioxidant properties. In the present study, antioxidant properties of some benzimidazole derivatives having aryl-methylene amino acetamide (1-12) (Table 1) which have previously been shown Epidermal Growth Factor Receptor (EGFR) kinase inhibitory activities were investigated.<sup>13</sup>

## EXPERIMENTAL

### *General Synthetic*

All the desired benzimidazole-derived compounds were synthesised as below. 2-phenyl-1H-benzo[d]imidazole (I) was produced via oxidative condensation of o-phenylenediamine, benzaldehyde and sodium metabisulfite (Scheme 1). Treatment of I with ethyl chloroacetate in KOH/DMSO yielded the N-alkylated products ethyl 2-(2-phenyl)-1H-benzo[d]imidazol-1-yl) acetate (II). Hydrazine hydrate and the ester (II) in ethanol were refluxed for 4h to obtain the desired hydrazide compounds, 2-(2-phenyl)-1H-benzo[d]imidazol-1-yl) acetohydrazide (III). Compounds 1-12 were achieved by condensing acyl hydrazide III with the corresponding aromatic aldehyde derivatives in the presence of sulfuric acid.<sup>13</sup>

### *Treatment of Animals*

Albino male Wistar rats with 200–225 g were used throughout the experiments. All animals were housed in single cages under controlled laboratory conditions (22–25°C room temperature; 12-h light-dark cycle; optimum humidity) and had access to standard rat chow and tap water *ad libitum*. They were deprived of feed for 24-h before sacrifice and then decapitated under anaesthesia. Their liver tissues were carefully dissected and immediately

stored in a freezer at -80°C. All procedures used in this study were approved by the Ethics Committee for Animal Experiments of Ankara University.

#### *Isolation of Rat Liver Microsomes*

The rat liver tissues were weighed and homogenized with 1.15% KCl (w/v) at 3 000 rpm on ice and centrifuged at 11 000 g for 25 mins. Once the supernatant fractions were then centrifuged again at 108 000 g for 60 mins, the pellets were mixed with 20% glycerol and were immediately stored at -80°C until use. Total protein levels of liver microsomes were measured by the method of Lowry et al.<sup>27</sup> using bovine serum albumin as a standard.

#### *In vitro Antioxidant Activity*

##### *Lipid Peroxidation (LPO) Assay*

The NADPH-dependent LPO level was carried out based on the optimum conditions described previously.<sup>28</sup> In this protocol, the control activity was determined as the pure diluent in which the chemicals were dissolved. Dimethyl sulfoxide (DMSO) was used as a control for synthesized compounds. The assay was, therefore, performed only in a solvent as a control, or the determined concentrations of compounds. The protocol was carried out as described by Wills<sup>29,30</sup> with some modifications by Bishayee and Balasubramanian.<sup>31</sup> The measurement of thiobarbituric acid reactive substances (TBARS) is the well-establish method for quantifying NADPH-dependent LPO levels. This method is based on the principle of spectrophotometrically measuring the coloured product formed by the reaction of TBA with malondialdehyde (MDA) at 532 nm. The amount of TBARS was then indicated as nanomole of malondialdehyde (MDA)/mg protein. 1 mL reaction mixture contains 0.2 mg microsomal protein, 62.5 mM potassium phosphate buffer (pH: 7.4), 0.2 mM Fe<sup>2+</sup>, 90 mM KCl, and cofactor (NADPH-generating system) consisting of 2.5 mM glucose-6-phosphate, 14.2 mM potassium phosphate buffer (pH 7.8), 2.5 mM MgCl<sub>2</sub>, 0.25 mM NADP<sup>+</sup>, and 1.0 U glucose-6-phosphate dehydrogenase. The reaction was initiated by the addition of NADPH-generating system and then allowed to incubate at 37 °C for 30 mins in a shaking water bath. At the end of the incubation, the reaction was terminated by the addition of 500 µL of 25% trichloroacetic acid (TCA), then centrifuged at 5 000 rpm for 20 mins to remove denatured proteins. 1 mL supernatant was combined with 0.5 mL of thiobarbituric acid (TBA) and the mixture was then boiled for 20 mins in a hot water bath. Finally, the absorbance was read spectrophotometrically at a wavelength of 532 nm. Whilst BHT was used as a standard, the control used in this assay was DMSO.

##### *7-Ethoxyresorufin O-deethylase (EROD) Assay*

7-Ethoxyresorufin O-deethylase (EROD) activity in rat liver microsomes was assayed as previously described by Burke et al.<sup>32</sup> 7-Ethoxyresorufin is a substrate for CYP1A1, and this enzyme converts it to resorufin that can be measured by spectrofluorimetrically. 1 mL typical optimized reaction mixture contains 0.2 mg rat liver microsomal protein, 1.0 mM 7-ethoxyresorufin as a substrate, 100 mM Tris-HCl buffer (pH 7.8), 12 mM albumin, 10<sup>-3</sup> M test compound, and NADPH-generating system consisting of 2.5 mM glucose-6-phosphate, 14.2 mM potassium phosphate buffer (pH 7.8), 2.5 mM MgCl<sub>2</sub>, 0.25 mM NADP<sup>+</sup>, and 1.0 U glucose-6-phosphate dehydrogenase. The reaction was initiated by the addition of NADPH-generating system and then allowed to incubate at 37 °C for 5 mins. The reaction was then stopped by the addition of 3 mL ice-cold methanol, then centrifuged at 5 000 rpm for 20 mins to remove denatured proteins. Finally, the absorbance was then measured spectrofluorimetrically at the excitation wavelength of 538 nm and the emission wavelength of 587 nm. Whilst caffeine was used as a standard, the control used in this assay was DMSO.


## **RESULTS, DISCUSSION and CONCLUSION**

The antioxidant effects of synthesized compounds on the rat liver microsomal NADPH-dependent LPO levels were ascertained by quantifying the amount of 2-thiobarbituric acid reactive substances (TBARS) formed in the reaction (Table 1). The results indicated that all

synthesized compounds at a concentration of  $10^{-3}$  M had LPO inhibitory activities except compound 6 which contains thiophene that well-known isoster of the phenyl ring as aryl group and the rates were in the range of 15-57%. Compounds 2, 4, 5, 9 and 12 have moderate inhibitory activity on LPO levels in the range of 31-45%. The most active compound 3 bearing *p*-bromophenyl substituent at the second position of benzimidazole ring led to 57% inhibition on LPO level while butylated hydroxytoluene displayed 65% inhibition at the same concentration.











The *in vitro* effects of compounds on rat liver microsomal EROD activity were also tested. The results showed that none of the synthesized compounds had a marked inhibitory effect on EROD activity. Almost all the compounds displayed slightly inhibitory activities (2-20%) on EROD when the value of caffeine is 85% (Table 1).




In our previous studies, we described the synthesis and antioxidant effects of 2-[2-(4-chlorophenyl)benzimidazole-1-yl]-N-(2-arylmethylene amino) acetamides on EROD activity and LPO levels.<sup>21,33</sup> When compared with the results obtained from these studies, benzimidazoles carrying 4-chloro phenyl ring at the second position were found to be more effective than benzimidazole counterpart carrying non-substituted phenyl rings for both assays.



**Scheme 1.** Synthetic route to compounds 1-12.

**Table 1.** *In vitro* effects of compounds 1-12 on liver LPO levels and EROD enzyme activities. Concentration in incubation medium ( $10^{-3}$  M). All the values are means  $\pm$  SD of three independent experiments.

Compound ds	Ar	EROD (pmol/mg/min )	% of Control	LPO (nmol/mg/min)	% of Control
1	4-chlorophenyl 	$33.41 \pm 1.64$	80	$11.67 \pm 0.89$	72
2	4-fluorophenyl 	$42.76 \pm 2.34$	103	$10.51 \pm 1.88$	65
3	4-bromophenyl 	$38.91 \pm 1.55$	94	$6.97 \pm 0.65$	43
4	3-nitrophenyl 	$38.55 \pm 1.07$	93	$8.94 \pm 2.13$	55
5	2-naphtyl 	$38.87 \pm 1.44$	93	$9.40 \pm 2.13$	58
6	3-methylthiophene- 2-yl 	$35.91 \pm 4.36$	86	$82.58 \pm 1.23$	508
7	4-benzyloxyphenyl 	$37.61 \pm 0.68$	91	$13.81 \pm 0.32$	85
8	2-chloro-5- nitrophenyl 	$42.98 \pm 3.49$	103	$11.84 \pm 0.66$	73
9	3,4- dibenzyloxyphenyl 	$37.29 \pm 0.98$	90	$10.10 \pm 1.31$	62
10	3-bromo-4- fluorophenyl 	$34.50 \pm 1.13$	83	$12.89 \pm 0.33$	79

					
<b>11</b>	2,4-dichlorophenyl 	40.65 ± 1.02	98	12.08 ± 1.47	74
<b>12</b>	4-chloro-3-nitrophenyl 	38.26 ± 1.52	92	11.15 ± 0.98	69
<b>BHT</b>		-	-	5.68 ± 0.22	35
<b>Caffeine</b>		6.41 ± 0.36	15	-	-
<b>DMSO</b>		41.53 ± 0.99	100	16.25 ± 1.45	100

## REFERENCES

1. Grune, T. Oxidants and Antioxidant Defence Systems. The Handbook of Environmental Chemistry Vol. 2: Reactions, Processes; Springer, Berlin, 2005.
2. Huang D, Ou B, Prior RL. The chemistry behind antioxidant capacity assays. J Agric Food Chem. 2005;53(6):1841–1856.
3. Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr. 1993;57:715S–725S.
4. Cadenas E, Packer L. Handbook of Antioxidants. 2<sup>nd</sup> ed. Revised and Expanded; Marcel Dekker: New York-Basel, 2002.
5. Ayhan-Kilcigil G, Tuncbilek M, Altanlar N, Goker H. Synthesis and antimicrobial activity of some new benzimidazole carboxylates and carboxamides, Il Farmaco. 1999;54:562-565.
6. Kus C, Sozudonmez F, Altanlar N. Synthesis and antimicrobial activity of some novel 2-[4-(substituted piperazin-/piperidin-1-ylcarbonyl)phenyl]-1H-benzimidazole derivatives. Arch Pharm Chem Life Sci. 2009;342:54–60.
7. Han-Bo L, Wei-Wei G, Vijai Kumar RT, Cheng-He Z, Rong-Xia G. Novel amino-pyrimidinyl benzimidazoles as potentially antimicrobial agents: Design, synthesis and biological evaluation. Eur J Med Chem. 2018;143:66-84.
8. Alp M, Goker H, Brun R, Yildiz S. Synthesis and antiparasitic and antifungal evaluation of 2'-Arylsubstituted-1H,1'H- [2,5']bisbenzimidazolyl-5-carboxamides. Eur J Med Chem 2009;44:2002–2008.
9. Goker H, Ayhan-Kilcigil G, Tuncbilek M, Kus C, Ertan R, Kendi E, Ozbey S, Fort M, Garcia C, Farré A. Synthesis and Antihistaminic H1-Activity of 1,2,5(6)-Tri-substituted Benzimidazoles. Heterocycles. 1999;51:2561–2573.
10. Al-Douh Mh, Sahib H, Osman H, Hamid S, Salhimi S. Anti-Proliferation Effects of Benzimidazole Derivatives on Hct-116 Colon Cancer and Mcf-7 Breast Cancer Cell Lines. Asian Pac J Cancer P. 2012;13:4075-4079.
11. Yadav S, Sinha D, Sing KS, Singh K. Novel Benzimidazole Analogs as Inhibitors of EGFR Tyrosine Kinase. Chem Biol Drug Des. 2012;80:625-630.
12. Hu Z, Ou L, Li S, Yang L. Synthesis and Biological Evaluation of 1-Cyano-2-Amino-Benzimidazole Derivatives as a Novel Class of Antitumor Agents. Med Chem Res. 2014;23:3029-3038.

13. Demirel S, Ayhan Kilcigil G, Kara Z, Guven B, Onay Besikci A. Synthesis and Pharmacologic Evaluation of Some Benzimidazole Acetohydrazide Derivatives as EGFR Inhibitors. *Turk J Pharm Sci.* 2017;14(3):285-289.
14. Jawaid AM, Anees AS, Ahsan AK, Zulphikar A. Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents. *Eur J Med Chem.* 2017;126:853-869.
15. Cheong JF, Zaffagni M, Chung I, Xu Y, Wang Y, Jernigan FE, Zetter BR, Sun L. Synthesis and anticancer activity of novel water soluble benzimidazole carbamates. *Eur J Med Chem.* 2018;144:372-385.
16. Nakano H, Inoue T, Kawasaki N, Miyataka H, Matsumoto H, Taguchi T, Inagaki N, Nagai H, Satoh T. Synthesis and Biological Activities of Novel Antiallergic Agents 5-Lipoxygenase Inhibiting Action. *Bioorg Med Chem.* 2000;8:373-380.
17. Can-Eke B, Puskullu MO, Buyukbingol E, Iscan M. Study on the antioxidant Capacities of Some Benzimidazoles in Rat Tissues. *Chem Biol Interact.* 1998;113:65-77.
18. Ayhan-Kilcigil G, Kus C, Coban T, Can-Eke B, M. Iscan. Synthesis and anti-oxidant Properties of Novel Benzimidazole Derivatives. *J Enzym Inhib Med Chem.* 2004;19(2):129-135.
19. Ayhan-Kilcigil G, Kus C, Coban T, Can-Eke B, Ozbey S, M. Iscan. Synthesis, Antioxidant and Radical Scavenging Activities of Novel Benzimidazoles. *J Enzym Inhib Med Chem.* 2005;20(5):503-514.
20. Ayhan-Kilcigil G, Kus C, Ozdamar ED, Can-Eke B, Iscan M. Synthesis and antioxidant Capacities of Some New Benzimidazole Derivatives. *Arch Pharm.* 2007;340(11):607-611.
21. Ayhan-Kilcigil G, Gurkan S, Coban T, Ozdamar ED, Can-Eke B. Synthesis and Evaluation of Antioxidant Properties of Novel 2-[2-(4-Chlorophenyl)Benzimidazole-1-yl]-N-(2-Arylmethylene Amino) Acetamides and 2-[2-(4-Chlorophenyl) Benzimidazole-1-yl]-N-(4-Oxo-2-Aryl-Thiazolidine-3-yl) Acetamides-I. *Chem Bio Drug Des.* 2012;79(5):869-877.
22. Ayhan-Kilcigil G, Kus C, Coban T, Can-Eke B, Ozdamar ED, Can-Eke B. Identification of a Novel Series of N-Phenyl-5-[(2-Phenylbenzimidazol-1-yl)Methyl]-1,3,4-Oxadiazol-2-Amines as Potent Antioxidants and Radical Scavengers. *Arch Pharm.* 2014;347(4):276-282.
23. Kus C, Ayhan-Kilcigil G, Can-Eke B, Iscan M. Synthesis and Antioxidant properties of Some Novel Benzimidazole Derivatives on Lipid Peroxidation in the Rat Liver. *Arch Pharm Res.* 2004;27(2):156-163.
24. Kus C, Ayhan-Kilcigil G, Ozbey S, Kaynak FB, Kaya M, Coban T, Can-Eke B. Synthesis and Antioxidant Properties of Novel N-Methyl-1,3,4-Thiadiazol-2-Amine and 4-Methyl-2H-1,2,4-Triazole-3(4H)-Thione Derivatives of Benzimidazole Class. *Bio Med Chem.* 2008;16(8):4294-4303.
25. Kerimov I, Ayhan-Kilcigil G, Can-Eke B, Altanlar N, Iscan M. (2007) Synthesis, Antifungal and Antioxidant Screening of Some Novel Benzimidazole Derivatives. *J Enzym Inhib Med Chem.* 2007;22(6):696-701.
26. Kerimov I, Ayhan-Kilcigil G, Ozdamar ED, Can-Eke B, Coban T, Ozbey S, Kazak C. Design and One-Pot and Microwave-Assisted Synthesis of 2-Amino/5-Aryl-1,3,4-Oxadiazoles Bearing a Benzimidazole Moiety as Antioxidants. *Arch Pharm.* 2012;345:549-556.
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJJ. Protein measurement with the Folin phenol reagent. *Biol Chem.* 1951;193(1):265-75.
28. Iscan M, Arinc E, Vural N, Iscan MY. In vivo effects of 3-methylcholantrene, phenobarbital, pyretrum and 2.4.5-T isooctylester on liver, lung and kidney microsomal

mixed-function oxidase system of guinea-pig: a comparative study. *Comp Biochem Physiol.* 1984;77C:77–190.

29. Wills ED. Mechanisms of lipid peroxide formation in animal tissues. *Biochem J.* 1966;99:667–676.

30. Wills ED. Lipid peroxide formation in microsomes. Relationship of hydroxylation to lipid peroxide formation. *Biochem J.* 1969;113:333–341.

31. Bishayee S, Balasubramanian AS. Lipid peroxide formation in rat brain. *J Neurochem.* 1971;18:909–920.

32. Burke MD, Thompson S, Elcombe CR, Halpert J, Haaparanta T, Mayer RT. Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. *Biochem Pharmacol.* 1985;34(18):3337–3345.

33. Alp AS, Kilcigil GA, Ozdamar ED, Coban T, Eke B. Synthesis and evaluation of antioxidant activities of novel 1,3,4-oxadiazole and imine containing 1H-benzimidazoles. *Turk J Chem.* 2015;39:42–53.